204 related articles for article (PubMed ID: 31479563)
1. Statin use and longitudinal changes in prostate volume; results from the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
Allott EH; Csizmadi I; Howard LE; Muller RL; Moreira DM; Andriole GL; Roehrborn CG; Freedland SJ
BJU Int; 2020 Feb; 125(2):226-233. PubMed ID: 31479563
[TBL] [Abstract][Full Text] [Related]
2. Statin Use and Lower Urinary Tract Symptoms Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial.
Kramer JJ; Gu L; Moreira D; Andriole G; Csizmadi I; Freedland SJ
J Urol; 2022 Feb; 207(2):417-423. PubMed ID: 34544265
[TBL] [Abstract][Full Text] [Related]
3. Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride.
Muller RL; Gerber L; Moreira DM; Andriole G; Hamilton RJ; Fleshner N; Parsons JK; Freedland SJ
Eur Urol; 2013 Jun; 63(6):1115-21. PubMed ID: 23541458
[TBL] [Abstract][Full Text] [Related]
4. Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study.
Freedland SJ; Hamilton RJ; Gerber L; Banez LL; Moreira DM; Andriole GL; Rittmaster RS
Prostate Cancer Prostatic Dis; 2013 Sep; 16(3):254-9. PubMed ID: 23567655
[TBL] [Abstract][Full Text] [Related]
5. Dutasteride is associated with reduced risk of transrectal prostate biopsy-associated urinary tract infection and related hospitalizations.
Moreira DM; Andriole GL; Nickel JC; Roehrborn CG; Castro-Santamaria R; Freedland SJ
World J Urol; 2017 Oct; 35(10):1525-1530. PubMed ID: 28396999
[TBL] [Abstract][Full Text] [Related]
6. Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial.
Fowke JH; Howard L; Andriole GL; Freedland SJ
Eur Urol; 2014 Dec; 66(6):1133-8. PubMed ID: 24568894
[TBL] [Abstract][Full Text] [Related]
7. Dutasteride in men receiving testosterone therapy: a randomised, double-blind study.
Kacker R; Harisaran V; Given L; Miner M; Rittmaster R; Morgentaler A
Andrologia; 2015 Mar; 47(2):148-52. PubMed ID: 24499051
[TBL] [Abstract][Full Text] [Related]
8. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
[TBL] [Abstract][Full Text] [Related]
9. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
10. Statin Use, Serum Lipids, and Prostate Inflammation in Men with a Negative Prostate Biopsy: Results from the REDUCE Trial.
Allott EH; Howard LE; Vidal AC; Moreira DM; Castro-Santamaria R; Andriole GL; Freedland SJ
Cancer Prev Res (Phila); 2017 Jun; 10(6):319-326. PubMed ID: 28487295
[TBL] [Abstract][Full Text] [Related]
11. MAPPED study design: a 6 month randomised controlled study to evaluate the effect of dutasteride on prostate cancer volume using magnetic resonance imaging.
Robertson NL; Moore CM; Ambler G; Bott SR; Freeman A; Gambarota G; Jameson C; Mitra AV; Whitcher B; Winkler M; Kirkham A; Allen C; Emberton M
Contemp Clin Trials; 2013 Jan; 34(1):80-9. PubMed ID: 23085153
[TBL] [Abstract][Full Text] [Related]
12. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.
Andriole G; Bostwick D; Brawley O; Gomella L; Marberger M; Tindall D; Breed S; Somerville M; Rittmaster R;
J Urol; 2004 Oct; 172(4 Pt 1):1314-7. PubMed ID: 15371831
[TBL] [Abstract][Full Text] [Related]
13. Effect of dutasteride on the risk of prostate cancer.
Andriole GL; Bostwick DG; Brawley OW; Gomella LG; Marberger M; Montorsi F; Pettaway CA; Tammela TL; Teloken C; Tindall DJ; Somerville MC; Wilson TH; Fowler IL; Rittmaster RS;
N Engl J Med; 2010 Apr; 362(13):1192-202. PubMed ID: 20357281
[TBL] [Abstract][Full Text] [Related]
14. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.
Fleshner NE; Lucia MS; Egerdie B; Aaron L; Eure G; Nandy I; Black L; Rittmaster RS
Lancet; 2012 Mar; 379(9821):1103-11. PubMed ID: 22277570
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
[TBL] [Abstract][Full Text] [Related]
16. The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study.
Jamnagerwalla J; Howard LE; Vidal AC; Moreira DM; Castro-Santamaria R; Andriole GL; Freedland SJ
J Urol; 2016 Sep; 196(3):715-20. PubMed ID: 27060053
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Properties of Total and Free Prostate-Specific Antigen to Predict Overall and Clinically Significant Prostate Cancer Among Men With Low Testosterone and Prior Negative Biopsy.
Schwarzman LS; Pagani RL; Ohlander SJ; Mima M; Abern MR; Andriole GL; Freedland SJ; Moreira DM
Urology; 2020 Mar; 137():97-101. PubMed ID: 31733275
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R
BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645
[TBL] [Abstract][Full Text] [Related]
19. The Effect of Dutasteride on Magnetic Resonance Imaging Defined Prostate Cancer: MAPPED-A Randomized, Placebo Controlled, Double-Blind Clinical Trial.
Moore CM; Robertson NL; Jichi F; Damola A; Ambler G; Giganti F; Ridout AJ; Bott SR; Winkler M; Ahmed HU; Arya M; Mitra AV; McCartan N; Freeman A; Jameson C; Castro R; Gambarota G; Whitcher BJ; Allen C; Kirkham A; Emberton M
J Urol; 2017 Apr; 197(4):1006-1013. PubMed ID: 27871928
[TBL] [Abstract][Full Text] [Related]
20. Baseline Prostate Atrophy is Associated with Reduced Risk of Prostate Cancer in Men Undergoing Repeat Prostate Biopsy.
Moreira DM; Bostwick DG; Andriole GL; Peterson BL; Cohen HJ; Castro-Santamaria R; Freedland SJ
J Urol; 2015 Nov; 194(5):1241-6. PubMed ID: 26165588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
